December #30 : Go Figure - by Scott Hess and Edited by RonniLyn Pustil

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents

Wild Kingdom

Rx Marijuana

Gender Matters

The Fabulous One

Mailbox

S.O.S.

Resistance Gets a Wellcome

Name in Vain

Go Figure

Like Butt-ah

An Aye for an Eye

To Russia Without Love

The Odd Couple

Secondhand Dose

Law and Disorder

AIDS in 2003

Catholic Cleanup

Until the Cure

Say What--December 1997

Diana, Princess of Wales

Chaka Treatment

Bear Essentials

Brace Yourself

All That Jazz

Respect Your Elders!

Bill of Health

Nunz With Attitude

POZ Picks-December 1997

Don't Mess With Mama

All Yesterday's Parties

The Light Burns Out

Peace of My Heart

Swing Your Partner

Once Upon a Lazarus

The Grim Reefer

In Case of Emergency

A DJ Saved My Life

Sweetness and Blight

"The First Cure"

Breaks for the Aches

Fishing for Supplements

When HIV Drugs Fail

Mary Fisher Gets Mad

Music Is Medicine



Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

December 1997

Go Figure

by Scott Hess and Edited by RonniLyn Pustil

HIV-consumer reports

In the first quarter of 1997, some 316,890 people with HIV sought treatment; Crixivan (indinavir) was the most-prescribed protease inhibitor (80,200 patients); about 40 percent of medical and prescription bills were paid for by Medicaid. These fun facts from the age of protease are available thanks to Scott Levin and his new HIV therapy Audit, a database of projected trends in HIVer service-and-drug consumption. A canny consultant to the pharmaceutical trade, Levin said the audit's purpose is "to understand the current scope of how physicians are treating the condition and examine current treatment patterns." Conventional audits do not capture the depth of data demanded by drug companies to deduce how docs are mixing and matching the new therapies, said Levin. Of course, it's the manufacturers of the new drugs that make up the bulk of Levin's clients. Not in Levin's database: The 95 percent of people with HIV worldwide who do not have access to protease cocktails.



[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV 101
HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
Disclosing Your Status
Starting Treatment
Search for the Cure
POZ Stories
POZ TV
Read the Blogs
Visit the Forums
Women
African American
Latino
Providers
Job Listings
Events Calendar


    andais
    Red House
    West Virginia


    Sloan1
    Dallas
    Texas


    latinpozdallas
    Dallas
    Texas


    kmfdm221
    Arcata
    California
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Can social media help stop HIV stigma?
Yes
No

Survey
Mind Matters

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.